News and Insights
Before J.P. Morgan: Make January an update, not an introduction
November 17, 2026
Five developments smaller life science leaders should consider as they prepare to meet investors, partners and media
For a smaller life science company, the next study may be taking shape while financing is still being secured and the search for a partner continues. January’s meetings in San Francisco bring those efforts together, offering time with people who could help the company move forward. How that time is used depends partly on what those people already know about the science and the team advancing it.
The countdown to the 2027 J.P. Morgan Healthcare Conference has begun, and preparation is already shaping the conversations that will take place in San Francisco. As investors book hotel rooms, prospective partners schedule meetings, and journalists choose stories to pursue, companies should be prepared to share what they have learned and how clinical findings guide the next steps in development. Give investors, partners and journalists a reason to follow your company now, so January’s meetings begin with an update, not an introduction.
Issued on the heels of last year’s conference, the J.P. Morgan February 2026 outlook highlighted technology, dealmaking, GLP-1s, Asia-Pacific investment and insurance coverage. For small to mid-sized biopharma and medical device companies, five related developments make the connection between clinical work and communication increasingly consequential. They concern the resources available to advance science, the evidence others need to assess it and the people who can help bring its promise closer to patients.
“At JPM, surviving the week takes stamina, but winning the week takes a strategy. Without a clear game plan and a tight narrative, even great science gets lost in the San Francisco noise,” says David Carey, senior partner, FINN Partners Health IR Group Lead.
Before the Deal, Confidence in the Team
A company seeking a partner early in development is asking another organization to commit resources while questions remain unanswered. The HSBC analysis of private biopharma licensing from 2023 through June 2025 found that discovery and preclinical programs represented 75% to 80% of deal volume in its dataset. Show prospective partners what the data establish, which questions remain, and what their investment enables the team to accomplish next.
Scientific presentations, publications and media conversations build recognition of the company’s clinical contribution and confidence in the operational team. Begin that work before a pivotal result creates urgency, giving clinicians, investors and prospective partners time to examine the evidence and get to know the leadership. Their questions can help sharpen the company’s positioning, while a consistent flow of information keeps its progress visible between milestones.
Prospective partners are watching how the team will handle upcoming decisions, including what happens when research challenges expectations. J.P. Morgan reported that upfront cash accounted for 6% of announced biopharma R&D licensing value through the third quarter of 2026, with much of that value contingent on future achievements. The commitment being considered, therefore, extends well beyond the next result. Discussing encouraging and disappointing findings openly, including how the team interprets them and decides what to do next, helps others understand the science and trustworthiness. People bet on teams and place their hopes on molecules.
Clinical findings must answer a question about care
That willingness to commit rests on understanding the value the research may bring to the marketplace and, eventually, to patients. Spencer Stuart’s 2025 biopharma outlook describes investors seeking more data and stronger evidence to enable companies to carry out their plans. Communication and clinical colleagues need to consider those expectations as studies are planned, with time to hear the questions that clinicians and patient advocates would raise. Those are the same questions that savvy investors and science-trained media will raise.
A biological change may advance scientific understanding while leaving questions about how patients feel, function or survive. The FDA distinguishes surrogate endpoints from direct measures of clinical benefit. For a device developer, that may mean showing how the result could inform diagnosis or treatment; for a therapy developer, it may mean explaining its relevance to patients whose existing options fall short. Each regulatory milestone should bring greater understanding of that intended contribution to care.
AI accelerates insights and conveys careful use of resources
Producing the evidence takes time, and IQVIA reports that clinical development timelines lengthened in 2025. For a smaller company, the value of AI may be measured by what its people can accomplish before they need to raise more money. Helping researchers find the information they need, share findings and avoid repeating work can save time and reduce development costs.
Choosing a tool begins with understanding how colleagues work together and make decisions. Some agentic AI tools may help connect information and coordinate tasks, while other applications address specific research needs. AIM-NASH, qualified by the FDA in December 2025, assists pathologists in assessing liver biopsies in clinical trials, with pathologists retaining responsibility for interpretation.
When improvements in data analysis or next-step direction can be demonstrated, explaining how the team used an insight to act sooner gives others a view of how leadership manages the resources entrusted to it. The discussion turns to progress toward a clinical milestone and attention to burn, with AI contribution made clear by what people accomplished.
Pressure on care access reaches into development
The resources needed to deliver care deserve attention too. A therapy requiring repeated visits may burden a family, while a device may demand time from a clinical team already stretched thin. Hearing those concerns during development allows leadership to consider the customer and system-wide friction its approach could remove or unintentionally add.
“At J.P. Morgan, every investor is looking for an opportunity. The companies that stand out answer three questions: Why now, who pays, and what’s the upside? Why now is the one that wins the room. You have to convince investors that the train leaves the station in 2027 and they need to be on it,” said Fern Lazar, managing partner, Global Health Practice Lead and a 20-time attendee at JPM.
Regulatory approval can leave a company facing another hurdle: who will cover the cost of care? The absence of a usable billing code or sufficient evidence to support coverage can delay access, even when physicians want to use the product. Smaller companies need to identify the reimbursement route and the data payers will require during development. In January’s discussions, leadership should be ready to describe that path, the remaining obstacles and the steps underway to secure coverage and patient access.
Entrepreneurial ambition is welcoming experience
The breadth of these decisions helps explain the appeal of people who have traveled this road before. Spencer Stuart describes companies seeking leaders who connect clinical execution with commercial value. Experienced life science professionals are also pursuing entrepreneurial opportunities as founders, directors and advisers, bringing knowledge and relationships that can complement a smaller team’s strengths.
The founders of Regeneron recognized that combination years ago. Roy Vagelos, MD, formerly Merck chairman and CEO, became its board chair in 1995 and helped guide its research priorities. Today, former Pfizer CSO Mikael Dolsten is the founding CEO and chairman of Quarry Thera and advises GV, while Michael Rosenblatt, the former chief medical officer at Merck, advises Flagship Pioneering and its companies on clinical development.
For leaders preparing for January, these examples invite consideration of who might bring wisdom and stature to their board table. A company’s public presence should help potential advisers understand its ambitions and where their experience could contribute.
Let the meeting build on what people know
As January’s calendars fill, every meeting request asks someone to choose where to spend their time. Use the weeks ahead to give that choice substance through publications, clinical commentary and media coverage that show what the company is learning and how its leaders are guiding the work. When people have followed the science and seen the team’s judgment through progress and setbacks, an invitation to meet can carry a reason to say yes.
“JPM can’t carry a company’s story for the entire year. January’s meetings become welcome updates when PR, investor relations, digital engagement and other industry conferences keep people informed between milestones,” says Ellie Hanson, senior partner and FINN Partners Israel Co-Lead. “That year-round communication gives investors time to understand the company’s value and reasons to engage when the industry heads to JPM in January.”
AI is becoming another way people curate those impressions. Someone preparing for a meeting may ask an AI system about the company’s science, leadership or progress (and setbacks). GEO extends the focus of SEO from finding information through search results to how that information appears in AI-generated answers. The company’s communications and independent coverage inform the response, making a consistent flow of accurate information part of the preparation for January.
Use these weeks to give people reasons to follow the company and understand its direction. Explain what the team has learned, how it is using its resources and what must happen next to advance development and patient access. When January arrives, what will make someone ready to commit their time, capital or experience to the work ahead?
